정신분열병 환자에서 항정신병약물 치료가 혈청 VEGF, sVEGFR-1 및 sVEGFR-2의 농도에 미치는 영향 - 예 비 연 구 - = The Effect of Antipsychotic Drug Treatment on Serum VEGF, sVEGFR-1, and sVEGFR-2 Level in Schizophrenia - A Preliminary Study -

국문 초록 (Abstract)

목 적: Cytokine 중의 하나인 vascular endothelial growth factor(VEGF)와 VEGF 수용체들은 다양한 생체내 조절 및 질병 상태와 연관이 있음이 알려져 있다. 본 연구는 정신분열병 환자에서 항정신병약물 치료에 따른 혈청내 자유(free) VEGF와 가용성 VEGFR-1, 가용성 VEGFR-2의 변화를 보기 위한 것이었다. 방 법: 각 환자들은 DSM-IV 진단기준에 의해 정신분열병으로 진단을 받았고, 약물투여 시작일을 기준으로 4주째 및 8주째에 추적 관찰하였다. 모두 13명이 환자군에 포함되었으며 항정신병약물 투여전과 투여후 4주째, 8주째에 각각 PANSS에 의한 상태 평가와 함께 자유 VEGF, sVEGFR-1, sVEGFR-2의 농도를 측정하였다. 13명의 정상 대조군을 환자군의 나이와 성별에 맞춰 선정하였다. 결 과: 정신분열병 환자군의 혈청 자유 VEGF($295.2{\pm}43.7$pg/ml)와 sVEGFR-2($8259{\pm}336.7$)의 농도는 정상 대조군($199.0{\pm}28.8$ 및 $8481{\pm}371.9$)과 비교하였을 때 의미있는 차이를 보이지 않았다. 그러나 sVEGFR-1의 농도($86.2{\pm}10.3$, p<0.05)는 정신분열병 환자군에서 대조군($59.0{\pm}6.4$)에 비해 의미있게 상승하였다. 정신분열병 환자군에서 항정신병약물 투여 후 자유 VEGF 농도는 4주째($338.9{\pm}56.5$)와 8주째($309.5{\pm}58.7$) 모두 투여 전과 비교하여 차이가 없었다. 그러나 sVEGFR-1 농도는 약물 치료후 8주째($57.3{\pm}6.3$, p<0.05)에 측정한 결과에서 유의하게 감소하였다. sVEGFR-2의 농도도 치료전과 비교하였을때 약물 치료후 4주째($7761{\pm}403.0$, p<0.05)와 8주째($7435{\pm}333.5$, p<0.05) 모두 유의하게 감소하였다. 결 론: sVEGFR-1과 sVEGFR-2 농도의 감소는 항정신병약물이 작용하는 도파민 신경계와 관련된 것으로 추정된다.

참고문헌 (Reference)

• 1 Zhang ZH, "[expression of mrna of vascular endothelial growth factor in a rat model of hyperoxia-induced retinopathy.]." 9 : 371-374, 2007
• 2 Holash J, "Vegf-trap: A vegf blocker with potent antitumor effects." 99 : 11393-11398, 2002
• 3 Boulton M, "Vegf localisation in diabetic retinopathy." 82 : 561-568, 1998
• 4 Cao L, Jiao X, Zuzga DS, Liu Y, Fong DM, Young D, et al, "Vegf links hippocampal activity with neurogenesis, learning and memory." 36 : 827-835, 2004
• 5 Fabel K, "Vegf is necessary for exercise-induced adult hippocampal neurogenesis." 18 : 2803-2812, 2003
• 6 Ohm JE, "Vegf inhibits t-cell development and may contribute to tumor-induced immune suppression." 101 : 4878-4886, 2003
• 7 Zhang ZG, "Vegf enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain." 106 : 829-838, 2000
• 8 Ohm JE, "Vegf as a mediator of tumor-associated immunodeficiency" 23 : 263-272, 2001
• 9 van Bruggen N, "Vegf antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain." 104 : 1613-1620, 1999
• 10 Yancopoulos GD, "Vascular-specific growth factors and blood vessel formation." 407 : 242-248, 2000
• 11 Nagy JA, "Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis." 196 : 1497-1506, 2002
• 12 Plate KH, "Vascular endothelial growth factor." 35 : 365-372, 1997
• 13 Sun Y, "Vascular endothelial growth factor-b (vegfb) stimulates neurogenesis: Evidence from knockout mice and growth factor administration." 289 : 329-335, 2006
• 14 Hahn RG, "Vascular endothelial growth factor in serum indicates cardiovascular risk in urology patients." 40 : 144-148, 2006
• 15 Robak E, "Vascular endothelial growth factor and its soluble receptors vegfr-1 and vegfr-2 in the serum of patients with systemic lupus erythematosus." 12 : 293-298, 2003
• 16 Klagsbrun M, "Vascular endothelial growth factor and its receptors." 7 : 259-270, 1996
• 17 Jin K, "Vascular endothelial growth factor (vegf) stimulates neurogenesis in vitro and in vivo." 99 : 11946-11950, 2002
• 18 Kremer C, "Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system." 57 : 3852-3859, 1997
• 19 Ha GC, "The preliminary study on the relationship between the serum vegf and clinical improvement in schizophrenia and depression." 3 : 95-99, 2005
• 20 Kay SR, "The positive and negative syndrome scale (panss) for schizophrenia." 261-276,
• 21 Basu S, "The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor." 7 : 569-574, 2001
• 22 Lee ES, "The levels of circulating vascular endothelial growth factor and soluble flt-1 in pregnancies complicated by preeclampsia." 22 : 94-98, 2007
• 23 de Vries C, "The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor." 989-991, science1992;255
• 24 Yasuhara T, "The differences between high and low-dose administration of vegf to dopaminergic neurons of in vitro and in vivo parkinson's disease model." 1038 : 1-10, 2005
• 25 Ferrara N, "The biology of vegf and its receptors." 9 : 669-676, 2003
• 26 Kierszniewska-Stepien D, "Serum vascular endothelial growth factor and its receptor level in patients with chronic obstructive pulmonary disease." 17 : 75-79, 2006
• 27 Coskun U, "Serum leptin, prolactin and vascular endothelial growth factor (vegf) levels in patients with breast cancer." 50 : 41-46, 2003
• 28 Muller JL, "Schizophrenia and parkinson's disease lead to equal motor-related changes in cortical and subcortical brain activation: An fmri fingertapping study." 57 : 562-568, 2003
• 29 Teunis MA, "Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system." 16 : 1465-1467, 2002
• 30 Jelkmann W, "Pitfalls in the measurement of circulating vascular endothelial growth factor." 47 : 617-623, 2001
• 31 Famulski W, "P53 correlates positively with vegf in preoperative sera of colorectal cancer patients." 53 : 43-48, 2006
• 32 Shibuya M, "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene closely related to the fms family" 519-524, oncogene1990;5
• 33 Rosenstein JM, "New roles for vegf in nervous tissue--beyond blood vessels." 187 : 246-253, 2004
• 34 Sugimoto H, "Neutralization of circulating vascular endothelial growth factor (vegf) by anti-vegf antibodies and soluble vegf receptor 1 (sflt-1) induces proteinuria." 278 : 12605-12608, 2003
• 35 Zachary I, "Neuroprotective role of vascular endothelial growth factor: Signalling mechanisms, biological function, and therapeutic potential." 14 : 207-221, 2005
• 36 Egan MF, "Neurobiology of schizophrenia." 7 : 701-707, 1997
• 37 Jain RK, "Molecular regulation of vessel maturation" 9 : 685-693, 2003
• 38 Baldwin ME, "Molecular control of lymphangiogenesis." 24 : 1030-1040, 2002
• 39 Ferrara N, "Molecular and biological properties of the vascular endothelial growth factor family of proteins." endocrrev1992;1318-32
• 40 Risau W, "Mechanisms of angiogenesis" 386 : 671-674, 1997
• 41 Gomez R, "Low-dose dopamine agonist administration blocks vascular endothelial growth factor (vegf)-mediated vascular hyperpermeability without altering vegf receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model." 147 : 5400-5411, 2006
• 42 Mann DR, "Leptin and pubertal development." 20 : 93-102, 2002
• 43 Cristina C, "Increased pituitary vascular endothelial growth factor-a in dopaminergic d2 receptor knockout female mice." 146 : 2952-2962, 2005
• 44 Tarkowski E, "Increased intrathecal levels of the angiogenic factors vegf and tgf-beta in alzheimer's disease and vascular dementia." 23 : 237-243, 2002
• 45 Terman BI, "Identification of the kdr tyrosine kinase as a receptor for vascular endothelial cell growth factor" armelli (armelli): 1579-1586,
• 46 Chaiworapongsa T, "Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia." 190 : 1541-1547, 2004
• 47 Fureder W, "Evaluation of angiogenesis and vascular endothelial growth factor expression in the bone marrow of patients with aplastic anemia." 168 : 123-130, 2006
• 48 Behzadian MA, "Effects of hypoxia on glial cell expression of angiogenesis-regulating factors vegf and tgf-beta." 24 : 216-225, 1998
• 49 Seeman P, "Dopamine receptors and the dopamine hypothesis of schizophrenia." 133-152, synapse1987;1
• 50 Lieberman JA, "Dopamine partial agonists: A new class of antipsychotic." 18 : 251-267, 2004
• 51 Pillai A, "Differential effects of haloperidol and olanzapine on levels of vascular endothelial growth factor and angiogenesis in rat hippocampus." 87 : 48-59, 2006
• 52 Chakroborty D, "Depleted dopamine in gastric cancer tissues: Dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis." 10 : 4349-4356, 2004
• 53 Levine RJ, "Circulating angiogenic factors and the risk of preeclampsia." 350 : 672-683, 2004
• 54 Lewis DA, "Catching up on schizophrenia: Natural history and neurobiology." 28 : 325-334, 2000
• 55 Rite I, "Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons." 101 : 1567-1582, 2007
• 56 Ray D, "Association of the vegf gene with proliferative diabetic retinopathy but not proteinuria in diabetes." 53 : 861-864, 2004
• 57 Potkin SG, "Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder." 60 : 681-690, 2003
• 58 Carmeliet P, "Angiogenesis in health and disease" 9 : 653-660, 2003
• 59 Ebos JM, "A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma." 2 : 315-326, 2004
• 60 Yi JS, ".[reliability and validity of the korean version of the positive and negative syndrome scale]." 40 : 1090-1105, 2001